Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: A case report

Cases Journal

Volumn 2, Issue 2, 2009, Pages

  Chan, Steven M ^a   George, Tracy ^a   Cherry, Athena M ^a   Medeiros, Bruno C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; DULOXETINE; GABAPENTIN; METHADONE; MEXILETINE; PREGABALIN; TOPIRAMATE;

ADULT; ARTICLE; BLOOD SMEAR; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CLINICAL EVALUATION; COUGHING; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; PARESTHESIA; PERIPHERAL NEUROPATHY; PLASMA CELL LEUKEMIA; SKIN BURNING SENSATION; SKIN TINGLING;

EID: 77953417951     PISSN: 17571626     EISSN: None     Source Type: Journal    
DOI: 10.1186/1757-1626-2-121     Document Type: Article

References (20)

1. Jimenez-Zepeda VH, Dominguez VJ: Plasma cell leukemia: a rare condition. Ann Hematol 2006, 85(4):263-267. (Pubitemid 43298673)
2. Sirohi B, Powles R: Multiple myeloma. Lancet 2004, 363(9412):875-887.
3. Richardson PG, Anderson KC: Bortezomib: a novel therapy approved for multiple myeloma. Clin Adv Hematol Oncol 2003, 1(10):596-600.
4. Katodritou E, Verrou E, Gastari V, Hadjiaggelidou C, Terpos E, Zervas K: Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? Leuk Res 2008, 32(7):1153-1156.
5. Kruger WH, Kiefer T, Schuler F, Lotze C, Busemann C, Dolken G: Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation. Onkologie 2007, 30(4):193-195. (Pubitemid 46482162)
6. Esparis-Ogando A, Alegre A, Aguado B, Mateo G, Gutierrez N, Blade J, Schenkein D, Pandiella A, San Miguel JF: Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005, 114(4):665-667. (Pubitemid 40349629)
7. Al-Nawakil C, Tamburini J, Bardet V, Chapuis N, Bourry E, Roux C, Park S, Choquet S, Dreyfus F, Bouscary D: Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leuk Lymphoma 2008, 49(10):2012-2014.
8. Musto P, Rossini F, Gay F, Pitini V, Guglielmelli T, D'Arena G, Ferrara F, Filardi N, Guariglia R, Palumbo A: Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 2007, 109(11):2285-2290. (Pubitemid 46801559)
9. Popat R, Oakervee HE, Hallam S, Curry N, Odeh L, Foot N, Esseltine DL, Drake M, Morris C, Cavenagh JD: Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol 2008, 141(4):512-516. (Pubitemid 351550543)
10. Yeung J, Chang H: Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma. J Clin Pathol 2007.
11. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, et al.: International uniform response criteria for multiple myeloma. Leukemia 2006, 20(9):1467-1473. (Pubitemid 44264086)
12. Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, Narimatsu H, Fujii T, Kawabata M, Taniguchi S, et al.: Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006, 107(9):3492-3494.
13. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, et al.: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006, 24(19):3113-3120. (Pubitemid 46638949)
14. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Hoyer JD, Harrington D, et al.: Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002, 99(10):3735-3741. (Pubitemid 34534545)
15. Soverini S, Cavo M, Cellini C, Terragna C, Zamagni E, Ruggeri D, Testoni N, Tosi P, De Vivo A, Amabile M, et al.: Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood 2003, 102(5):1588-1594. (Pubitemid 37022546)
16. Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, Chng WJ, Ketterling RP, Gertz MA, Henderson K, et al.: Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008. (Pubitemid 351689887)
17. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, et al.: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003, 101(6):2377-2380. (Pubitemid 36302084)
18. Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, et al.: Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007, 25(25):3892-3901. (Pubitemid 47477266)
19. Gotoh A, Ohyashiki K, Oshimi K, Usui N, Hotta T, Dan K, Ikeda Y: Lung injury associated with bortezomib therapy in relapsed/ refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical hematology. Int J Hematol 2006, 84(5):406-412.
20. Zappasodi P, Dore R, Castagnola C, Astori C, Varettoni M, Mangiacavalli S, Lazzarino M, Corso A: Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma. J Clin Oncol 2007, 25(22):3380-3381. (Pubitemid 47325628)